AstraZeneca CEO Pascal Soriot’s Pay Rises to £17.7 Million in 2025 as Bonuses Increase
REUTERS/Kent Nishimura
AstraZeneca Chief Executive Pascal Soriot saw his total compensation rise by 6.4 percent to £17.7 million in 2025, according to the company’s annual report released Tuesday. The increase was largely driven by higher annual bonuses following strong earnings performance.
AstraZeneca remains London’s most valuable listed company and has reported significant growth in revenue and profits in recent years, supported by its expanding portfolio of cancer, rare disease, and respiratory treatments. Soriot has led the pharmaceutical giant since 2012 and is widely credited with steering its global expansion.
The annual report showed Soriot received an annual bonus of £4.3 million for 2025, representing an increase of about 22 percent compared with 2024. His overall pay package includes salary, bonuses, long-term incentives, and pension benefits. The pay rise keeps him among the highest-paid executives in the FTSE 100.
Executive pay continues to draw attention from investors and governance groups, especially as companies balance shareholder returns with compensation structures. AstraZeneca has maintained that its pay policy is performance-linked.
The compensation increase reflects AstraZeneca’s strong earnings momentum and strategic investments in research and global markets. Leadership continuity is seen as important as the company pushes further innovation.
Soriot’s 2025 pay rise highlights AstraZeneca’s growth trajectory and the ongoing debate over executive compensation at major global firms.